Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
Recent posts
By the time you read this, I’ve probably already wrapped up my work as a correspondent for Xconomy, turned in my key to office on Rogers Street in Cambridge, MA, and... Read more »
Cambridge, MA-based Sedo, which provides an online marketplace for Web domain names, said today that it brokered UK-based Media Corp.’s sale of the “gambling.com” domain for $2.5 million to an unnamed... Read more »
Vertex Pharmaceuticals (NASDAQ:VRTX) faces a test today for its experimental drug for hepatitis C virus, telaprevir, as the FDA Antiviral Drugs Advisory Committee meets today in Silver Springs, MD,... Read more »
Cambridge, MA-based biotech Genzyme, now a unit of Sanofi-Aventis (NYSE:SNY), has amended its patent infringement lawsuit against its competitor Anika Therapeutics (NASDAQ:ANIK) related to Anika’s osteoarthritis treatment,... Read more »
A new cancer care startup called KEW Group has been quietly operating in the Boston area and entered advanced talks to raise a sizable amount from venture investors. With an ensemble... Read more »
SR One, the independent venture arm of London-based drug giant GlaxoSmithKline (NYSE:GSK), has established a San Francisco office after a long history of backing West Coast biotechs such as... Read more »
Biogen Idec’s (NASDAQ:BIIB) stock price is soaring this morning after the Weston, MA-based biotech company reported a bump in first quarter revenue and new details about a successful late-stage... Read more »
BG Medicine (NASDAQ:BGMD) took the long road to becoming a public company, scrapping its first attempt in 2008 and then spending just more than a year to wrap up... Read more »
Humedica, a Boston-based clinical informatics company, has raised $20 million in a round of equity financing, according to an SEC filing. The firm, which previously raised $30 million from Bain... Read more »
Ariad Pharmaceuticals (NASDAQ:ARIA), a Cambridge, MA-based developer of cancer drugs, said today it extended licenses to its cell-signaling regulation technology to three separate groups, all of which are using... Read more »
Investors are rewarding Bluebird Bio for wracking up accolades with its experimental gene therapies for serious genetic diseases. The Cambridge, MA-based biotech firm has brought in $30 million in a Series... Read more »
Cambridge, MA-based Alnylam Pharmaceuticals (NASDAQ:ALNY) has found another partner to help it deliver its gene-silencing drugs to tissues deep in the body. Precision NanoSystems, of Vancouver, British Columbia, has... Read more »
Cambridge, MA-based Atlas Venture and the agribusiness giant Monsanto (NYSE: MON) are working together to find interesting life sciences investments to complement Monsanto’s agriculture business, Monsanto said today. It’s another... Read more »
Taris Biomedical, an MIT spinout focused on treating bladder diseases, has brought on Third Rock Ventures as its new investor and lead backer in an $18.3 million Series B round of... Read more »
Nano Terra, a Brighton, MA-based company that works with industry on surface engineering and nanotechnology projects, said today that it has acquired the drug developer Surface Logix. The terms and details... Read more »
Michelle Browner saw firsthand what huge challenges lie along the way to developing a new drug during her 18 years at Swiss healthcare giant Roche. Now, Xconomy has learned, she has... Read more »
Aveo Pharmaceuticals (NASDAQ:AVEO), a Cambridge, MA-based company with a drug in late-stage development for advanced kidney cancer, said today that it has recruited biotech bigwig Henri Termeer, the outgoing... Read more »
[Updated. 4/8/11. 8:09 am Eastern. See updates to section on On-Q-ity.] T2 Biosystems has chosen deadly blood-borne yeast infections as the lead targets of its system for rapidly and accurately diagnosing... Read more »
New York is famous in the business world for its large companies in a variety of industries. For the partners at the seed-stage venture fund Founder Collective, however, the focus... Read more »
On the heels of a favorable FDA advisory panel vote on its experimental antibiotic, San Diego-based Optimer Pharmaceuticals (NASDAQ:OPTR) says today that Cubist Pharmaceuticals (NASDAQ:CBST) has agreed... Read more »
